FeesSafety
Pluang+

Olin declares $0.20 quarterly dividend, marking 100 years of consecutive payments.

Company Fundamentals
11 Nov 2026, 23:01 WIB
PRNewsWire
View Source
Bullish
Olin declares $0.20 quarterly dividend, marking 100 years of consecutive payments.

Olin Corporation announced a quarterly dividend of $0.20 per share, celebrating 100 years and 400 consecutive quarterly dividend payments. This milestone highlights Olin's long-term financial strength and commitment to shareholder value through various economic cycles. The dividend will be paid on December 11, 2026, to shareholders recorded by November 27, 2026. Olin remains focused on disciplined capital allocation and business growth to continue delivering value in the future.

Olin Corporation's milestone of 100 years of consecutive quarterly dividends provides context for readers interested in long-term financial resilience. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Nov 12, 2026 00:32 WIB: Among 83 priced US stocks, 47 rose and 36 fell. Notably, Freeport-McMoRan Inc (FCX) traded at USD 62.54 with a 3.71% gain and a typical hold time of 72 days, while Calumet Inc. (CLMT) and Dow Inc (DOW) both saw over 3% gains with shorter and longer hold times respectively, highlighting varied investor engagement.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
2 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Kiniksa Pharmaceuticals to present at Jefferies Global Healthcare Conference in London on Nov 16, 2026

Kiniksa Pharmaceuticals to present at Jefferies Global Healthcare Conference in London on Nov 16, 2026

Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. The event will be webcast live and available for replay on the ...

Market News
Neutral
5 hours ago
Lakefront Biotherapeutics posts Q3 2026 profit, advances autoimmune drug gamgertamig, plans €50M share buyback

Lakefront Biotherapeutics posts Q3 2026 profit, advances autoimmune drug gamgertamig, plans €50M share buyback

Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...

Company Fundamentals
Bullish
5 hours ago
DeFi Development tokenizes CHAD preferred stock for onchain trading on Solana and other blockchains.

DeFi Development tokenizes CHAD preferred stock for onchain trading on Solana and other blockchains.

DeFi Development Corp. has tokenized its Variable Rate Series C Perpetual Preferred Stock (CHAD) in partnership with xStocks, creating CHADx, a 1:1 tokenized version available on Solana and nine other blockchains. This innovation allows investors to ...

Company Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App